Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (61-70 of 361) with videos related to

Pageof 37
Sort By:
The Journal of Urology|June 11, 2005
Update on chemotherapy for advanced bladder cancerJonathan E Rosenberg, Peter R Carroll, Eric J Small
Urologic Oncology|September 12, 2006
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cellsAmy M Lin, Robert M Hershberg, Eric J Small
Oncology (Williston Park, N.Y.)|June 17, 2017
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic ImplicationsRahul R Aggarwal, Felix Y Feng, Eric J Small
The Lancet. Oncology|October 5, 2007
Androgen-response elements in hormone-refractory prostate cancer: implications for treatment developmentAndrew C Hsieh, Eric J Small, Charles J Ryan
Critical Reviews in Oncology/Hematology|December 13, 2006
Intermittent chemotherapy for metastatic hormone refractory prostate cancerAmy M Lin, Charles J Ryan, Eric J Small
Clinical Prostate Cancer|July 5, 2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancerGarth Beinart, Brian I Rini, Vivian Weinberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomesRahul Aggarwal, Tian Zhang, Eric J Small, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerBrian I Rini, Vivian Weinberg, Robert Bok, et al.
Cancer|August 1, 2007
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancerSusan Halabi, San-San Ou, Nicholas J Vogelzang, et al.
Preventive Oncology & Epidemiology|March 25, 2024
Cancer Research in 2030: A unique strategic planning process at a comprehensive cancer centerErin M Bank, Eric J Small, Alan Ashworth, et al.
Pageof 37

Showing results (61-70 of 361) with videos related to

Sort By:
Pageof 37
The Journal of Urology|June 11, 2005
Update on chemotherapy for advanced bladder cancerJonathan E Rosenberg, Peter R Carroll, Eric J Small
Urologic Oncology|September 12, 2006
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cellsAmy M Lin, Robert M Hershberg, Eric J Small
Oncology (Williston Park, N.Y.)|June 17, 2017
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic ImplicationsRahul R Aggarwal, Felix Y Feng, Eric J Small
The Lancet. Oncology|October 5, 2007
Androgen-response elements in hormone-refractory prostate cancer: implications for treatment developmentAndrew C Hsieh, Eric J Small, Charles J Ryan
Critical Reviews in Oncology/Hematology|December 13, 2006
Intermittent chemotherapy for metastatic hormone refractory prostate cancerAmy M Lin, Charles J Ryan, Eric J Small
Clinical Prostate Cancer|July 5, 2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancerGarth Beinart, Brian I Rini, Vivian Weinberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomesRahul Aggarwal, Tian Zhang, Eric J Small, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerBrian I Rini, Vivian Weinberg, Robert Bok, et al.
Cancer|August 1, 2007
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancerSusan Halabi, San-San Ou, Nicholas J Vogelzang, et al.
Preventive Oncology & Epidemiology|March 25, 2024
Cancer Research in 2030: A unique strategic planning process at a comprehensive cancer centerErin M Bank, Eric J Small, Alan Ashworth, et al.
Pageof 37